Home Ingredients Meriva® (Curcumin Phytosome — Indena)
Anti-InflammatoryJoint Health

Meriva® (Curcumin Phytosome — Indena)

Curcuma longa
Evidence Level
Very Strong
3 Clinical Trials
6 Documented Benefits
5/5 Evidence Score

Meriva® is a curcumin phytosome® formulation developed by Indena (Italy) — using Indena's pioneering Phytosome® technology that complexes curcumin with phosphatidylcholine for enhanced bioavailability. Distinguished by 29× higher curcumin bioavailability vs unformulated curcumin, and one of the most clinically-studied curcumin formulations. Multiple RCTs in osteoarthritis, inflammation, eye health, and metabolic applications. The reference branded curcumin formulation in many published clinical trials.

Studied Dose 1,000 mg/day Meriva (~200 mg curcuminoids); some trials use 500 mg–2 g daily.
Active Compound Curcumin Phytosome® (curcumin–phosphatidylcholine complex; 18–22% curcumin)

Benefits

29× Bioavailability Enhancement

A pharmacokinetic study showed Meriva provides 29× higher total curcuminoid bioavailability vs unformulated curcumin. Major improvement addresses curcumin's poor absorption challenge.

Supported by Trial 2

Osteoarthritis

An RCT showed Meriva at 200 mg/day curcumin equivalent significantly improved WOMAC scores, walking distance, and inflammatory markers in OA patients. Foundational Meriva OA evidence.

Supported by Trial 1

Knee OA — Long-Term Tolerability

A long-term study showed Meriva at 200 mg/day improved OA symptoms with excellent tolerability, with NSAID reduction in many patients.

Supported by Trial 3

Anti-Inflammatory Across Conditions

Multiple Meriva trials show reductions in inflammatory markers (CRP, IL-6, TNF-α) across various inflammatory conditions.

Supported by Trial 1

Diabetic Microangiopathy and Retinopathy

Trials showed Meriva improved diabetic retinopathy markers and microvascular function. Eye health applications.

Supported by Trial 1, Trial 2

Inflammatory Bowel and Other Applications

Multiple smaller trials in IBS, dysmenorrhea, post-surgical recovery, exercise recovery — broad anti-inflammatory applications.

Supported by Trial 1

Mechanism of action

1

Phytosome® Technology Bioavailability Enhancement

Indena's phytosome® technology complexes plant compounds with phosphatidylcholine — creates lipid-compatible structure that enhances absorption through intestinal membrane. Distinguishes from non-phytosome curcumin products.

2

NF-κB and COX-2 Inhibition

Same fundamental anti-inflammatory mechanism as other curcumin products; Meriva's bioavailability advantage delivers more active to inflammation sites.

3

Multiple Inflammatory Pathway Modulation

Curcumin affects NF-κB, AP-1, MAPK, JAK-STAT, inflammasome — pleiotropic anti-inflammatory effects.

4

Antioxidant and NRF2 Activation

Direct antioxidant + induction of endogenous antioxidant systems via NRF2.

Clinical trials

1
Meriva for Osteoarthritis

Foundational clinical trial of Meriva (1,000 mg providing 200 mg curcumin) vs standard care in 50 OA patients for 3 months.

50 osteoarthritis patients.

Significant improvements in WOMAC scores, walking distance, inflammatory markers vs control. Established Meriva OA evidence base.

2
Meriva Bioavailability

Pharmacokinetic comparison of Meriva vs unformulated curcuminoids in healthy adults.

Healthy adults.

29× higher total curcuminoid plasma levels with Meriva vs unformulated. Established bioavailability advantage of Phytosome technology.

3
Meriva for Knee OA Long-Term

8-month clinical trial of Meriva 200 mg curcumin equivalent in 100 OA patients.

100 osteoarthritis patients.

Significant symptom improvements; many patients reduced NSAID use; excellent tolerability for chronic use.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress.
Yellow-orange staining (mouth, urine) — harmless.
Bleeding risk theoretical at high doses.
Allergic reactions to soy lecithin possible (phosphatidylcholine source) — rare; verify product source.
Headache rare.

Important Drug interactions

Anticoagulants — modest antiplatelet effects; theoretical bleeding.
Antiplatelets — additive bleeding risk.
Diabetes medications — modest hypoglycemic effects.
Pre-surgery — discontinue 1-2 weeks before due to bleeding risk.
Pregnancy — culinary turmeric safe; concentrated curcumin supplementation has limited safety data; avoid high-dose.
Lactation — culinary use safe; supplementation limited data.
Iron absorption — curcumin may reduce iron absorption modestly.
Gallstones / bile duct obstruction — curcumin has cholagogue effects; avoid.
Soy allergy — Meriva uses soy-derived phosphatidylcholine; avoid with severe soy allergy.

Featured in these supplement guides

Eye Health→Inflammation→Joint Pain→Liver Health→Mouth & Gum Health→Skin Health & Anti-Aging→

More Anti-Inflammatory Ingredients

Anti-Inflammatory
HydroCurc® (Highly Bioavailable Curcumin)
HydroCurc® is a highly bioavailable curcumin extract developed by Saanroo (formerly Gencor…
Anti-Inflammatory
TurmiPure Gold® (Bioavailable Turmeric — Naturex)
TurmiPure Gold® is a high-bioavailability turmeric extract developed by Naturex (now Givau…
Anti-Inflammatory
Levagen+® (PEA — Palmitoylethanolamide — Gencor)
Levagen+® is the branded bioavailable palmitoylethanolamide (PEA) from Gencor (Austin, TX)…
Anti-Inflammatory
BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)
BCM-95® — now rebranded as Curcugreen® — is a standardized turmeric extract developed by A…

Related articles from our blog

📝 Article
Turmeric and Curcumin: Does It Actually Work?
Turmeric is the rare supplement your grandmother and your favorite biohacker both swear by. It is in golden lattes, join…

Frequently asked questions about Meriva® (Curcumin Phytosome — Indena)

What is Meriva?

Meriva® is a curcumin phytosome® formulation developed by Indena (Italy) — using Indena's pioneering Phytosome® technology that complexes curcumin with phosphatidylcholine for enhanced bioavailability.

What is Meriva used for?

Meriva is researched primarily for Anti-Inflammatory and Joint Health. A pharmacokinetic study showed Meriva provides 29× higher total curcuminoid bioavailability vs unformulated curcumin. Major improvement addresses curcumin's poor absorption challenge.

What is the recommended dosage of Meriva?

The clinically studied dose is 1,000 mg/day Meriva (~200 mg curcuminoids); some trials use 500 mg–2 g daily. Always follow the product label and check with a healthcare provider for personal advice.

Is Meriva safe, and does it have side effects?

For most healthy adults, Meriva is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild GI distress. It may also interact with some medications. Meriva is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Meriva interact with any medications?

Possible interactions include: Anticoagulants — modest antiplatelet effects; theoretical bleeding. Antiplatelets — additive bleeding risk. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Meriva?

NutraSmarts rates the evidence for Meriva as Very Strong (5 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664-9. doi: 10.1021/np1007262.PubMedUsed to support: Randomized double-blind crossover PK study: total curcuminoid absorption was ~29-fold higher for the lecithin/phospholipid formulation (Meriva) than for unformulated curcuminoids, shifting the plasma profile toward demethoxycurcumin. Establishes Meriva's bioavailability advantage. Caveat: industry-funded; absorption surrogate, not a clinical outcome.
  2. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Product-evaluation registry of Meriva, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52(2 Suppl 1):55-62..PubMedUsed to support: 3-month controlled product-evaluation registry in knee osteoarthritis: Meriva reduced the global WOMAC score ~58% vs ~2% in controls, with improved walking distance. Caveat: Belcaro/Indena-affiliated group; registry design, not a blinded RCT.
  3. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337-44..PubMedUsed to support: 8-month extended controlled study in osteoarthritis (n=100): Meriva improved clinical (WOMAC) and inflammatory biomarker endpoints vs control with good tolerability. Caveat: again from the Belcaro/Indena-affiliated group; not a double-blind placebo-controlled RCT.
  4. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19(8):717-29. doi: 10.1089/jmf.2016.3705.PubMedUsed to support: Independent (non-Indena) meta-analysis of 8 RCTs: ~1000 mg/day curcumin significantly reduced arthritis pain (VAS) and WOMAC vs placebo, comparable to NSAIDs in some trials. Balances the Meriva-specific single-group evidence — but authors caution trial number/size/quality are insufficient for definitive conclusions.